Interviews

Reducing data silos and boosting transparency in oncology requires payer-provider trust and co-governance, according to Vishnukamal Golla, MD, MPH.

Five experts share their key takeaways from Patient-Centered Oncology Care® (PCOC) 2025, highlighting AI integration and collaboration to improve care.

Programs such as Meds to Bed can work in tandem with retail pharmacies to offer accessible medications for patients.

Although overall costs have not declined with the Oncology Care Model (OCM), supportive care costs have decreased through greater use of cost-effective therapies.

Timothy W. Cutler, PharmD, associate chief of ambulatory care at UC Davis Health, describes how pharmacy services patients healthy and out of the hospital.

Vivek Subbiah, MD, considers artificial intelligence (AI) and comprehensive somatic and germline testing essential for guiding precision oncology and improving patient care.

Despite an executive order aimed at addressing homelessness in the US, defunding vital programs could spell difficulty in helping the homeless.

Primary aldosteronism is often overlooked in hypertension. Educating providers and utilizing tools can enhance screening and treatment effectiveness, emphasizes Vivek Bhalla, MD, Stanford.

Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.

Oncology pharmacists now work alongside providers to improve efficiency, patient education, and treatment outcomes, according to Scott Soefje, PharmD, MBA, BCOP.

Tory M. Wolff, MBA, discusses his study showing that frequent routine primary care visits may lower costs for higher-risk commercially insured adults.

Oncology care requires teamwork, support services, and careful planning to ensure effective, affordable, and patient-focused treatment, according to Brian Mulherin, MD.

Emma Guttman-Yassky, MD, PhD, discusses the long-term efficacy of deuruxolitinib in alopecia areata.

Prior authorizations can affect both health system operations and worsen physician burnout.

Social inequalities significantly impact COPD and PH outcomes, highlighting the need for systemic health care solutions, emphasizes Lucilla Piccari, MD, PhD, Hospital del Mar.

Hope Krebill of the Masonic Cancer Alliance at the University of Kansas Medical Center outlines patient navigation models that improve outcomes and reduce missed appointments.

The MajesTEC-5 trial shows teclistamab's impressive efficacy in achieving MRD-negative status in newly diagnosed transplant-eligible patients, explains Marc S. Raab, MD, PhD.

Research reveals strong connections between muscle strength and cognitive function in patients with COPD, highlighting the potential for rehabilitation strategies.

Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, explore how understanding MG subtypes and patient characteristics enhances targeted therapy and personalized treatment.

Research exploring protective mechanical ventilation strategies for acute respiratory distress syndrome was presented at the ERS Congress by Luca Menga, MD, University of Toronto.

Michaela Nuttal, MS, explores the complex culture of smoking among nurses, highlighting challenges and motivations for quitting within health care settings.

Nerandomilast for idiopathic pulmonary fibrosis potentially improves survival and slows disease progression, explains Justin Oldham, MD, PhD, MS, FIBRONEER steering committee member.

Laxmi Patel urges rural hospitals to align leadership early and build logic models to show how transformation funds can drive access, equity, and sustainability.

David Mitchell, PharmD, MBA, UC Davis, shares how collaboration between health systems and manufacturers is transforming patient access and outcomes for rare disease treatments.

Emma Guttman, MD, PhD, discusses the promising potential of rocatinlimab in targeting the OX40-OX40 ligand pathway for atopic dermatitis treatment.

Expanding community-based cancer services brings advanced treatments closer to home and addresses social determinants of health, says Kathy Oubre, MS.

Davey Daniel, MD, shares strategies to prevent bias in artificial intelligence (AI) and outlining future opportunities for its adoption in precision oncology.

Christopher Carlin, MBChB, PhD, explores the potential of AI-driven insights to enhance COPD care and identify candidates for biologic therapy.